Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging

Omran Abuaboud, Samy L. Habib, Josephine Trott, Benjamin Stewart, Sitai Liang, Abhijit Chaudhari, Julie Sutcliffe, Robert H Weiss

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Many cancers appear to activate intrinsic antioxidant systems as a means to counteract oxidative stress. Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogenous glutamine for growth and exhibit reprogrammed glutamine metabolism, at least in part due to the glutathione pathway, an efficient cellular buffering system that counteracts reactive oxygen species and other oxidants. We show here that ccRCC xenograft tumors under the renal capsule exhibit enhanced oxidative stress compared with adjacent normal tissue and the contralateral kidney. Upon glutaminase inhibition with CB-839 or BPTES, the RCC cell lines SN12PM-6-1 (SN12) and 786-O exhibited decreased survival and pronounced apoptosis associated with a decreased GSH/GSSG ratio, augmented nuclear factor erythroid-related factor 2, and increased 8-oxo-7,8-dihydro-2'-deoxyguanosine, a marker of DNA damage. SN12 tumor xenografts showed decreased growth when treated with CB-839. Furthermore, PET imaging confirmed that ccRCC tumors exhibited increased tumoral uptake of 18F-(2S,4R)4-fluoroglutamine compared with the kidney in the orthotopic mouse model. This technique can be utilized to follow changes in ccRCC metabolism in vivo. Further development of these paradigms will lead to new treatment options with glutaminase inhibitors and the utility of PET to identify and manage patients with ccRCC who are likely to respond to glutaminase inhibitors in the clinic.

Original languageEnglish (US)
Pages (from-to)6746-6758
Number of pages13
JournalCancer Research
Volume77
Issue number23
DOIs
StatePublished - Dec 1 2017

Fingerprint

Kidney Neoplasms
Glutamine
Renal Cell Carcinoma
Glutaminase
Oxidative Stress
Neoplasms
Kidney
Heterografts
Glutathione Disulfide
Growth
Oxidants
DNA Damage
Capsules
Glutathione
Reactive Oxygen Species
Antioxidants
Apoptosis
Cell Line
Survival
CB-839

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging. / Abuaboud, Omran; Habib, Samy L.; Trott, Josephine; Stewart, Benjamin; Liang, Sitai; Chaudhari, Abhijit; Sutcliffe, Julie; Weiss, Robert H.

In: Cancer Research, Vol. 77, No. 23, 01.12.2017, p. 6746-6758.

Research output: Contribution to journalArticle

@article{75bb3bb3c14f419ab8f7d528a637fbf5,
title = "Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging",
abstract = "Many cancers appear to activate intrinsic antioxidant systems as a means to counteract oxidative stress. Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogenous glutamine for growth and exhibit reprogrammed glutamine metabolism, at least in part due to the glutathione pathway, an efficient cellular buffering system that counteracts reactive oxygen species and other oxidants. We show here that ccRCC xenograft tumors under the renal capsule exhibit enhanced oxidative stress compared with adjacent normal tissue and the contralateral kidney. Upon glutaminase inhibition with CB-839 or BPTES, the RCC cell lines SN12PM-6-1 (SN12) and 786-O exhibited decreased survival and pronounced apoptosis associated with a decreased GSH/GSSG ratio, augmented nuclear factor erythroid-related factor 2, and increased 8-oxo-7,8-dihydro-2'-deoxyguanosine, a marker of DNA damage. SN12 tumor xenografts showed decreased growth when treated with CB-839. Furthermore, PET imaging confirmed that ccRCC tumors exhibited increased tumoral uptake of 18F-(2S,4R)4-fluoroglutamine compared with the kidney in the orthotopic mouse model. This technique can be utilized to follow changes in ccRCC metabolism in vivo. Further development of these paradigms will lead to new treatment options with glutaminase inhibitors and the utility of PET to identify and manage patients with ccRCC who are likely to respond to glutaminase inhibitors in the clinic.",
author = "Omran Abuaboud and Habib, {Samy L.} and Josephine Trott and Benjamin Stewart and Sitai Liang and Abhijit Chaudhari and Julie Sutcliffe and Weiss, {Robert H}",
year = "2017",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-17-0930",
language = "English (US)",
volume = "77",
pages = "6746--6758",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging

AU - Abuaboud, Omran

AU - Habib, Samy L.

AU - Trott, Josephine

AU - Stewart, Benjamin

AU - Liang, Sitai

AU - Chaudhari, Abhijit

AU - Sutcliffe, Julie

AU - Weiss, Robert H

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Many cancers appear to activate intrinsic antioxidant systems as a means to counteract oxidative stress. Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogenous glutamine for growth and exhibit reprogrammed glutamine metabolism, at least in part due to the glutathione pathway, an efficient cellular buffering system that counteracts reactive oxygen species and other oxidants. We show here that ccRCC xenograft tumors under the renal capsule exhibit enhanced oxidative stress compared with adjacent normal tissue and the contralateral kidney. Upon glutaminase inhibition with CB-839 or BPTES, the RCC cell lines SN12PM-6-1 (SN12) and 786-O exhibited decreased survival and pronounced apoptosis associated with a decreased GSH/GSSG ratio, augmented nuclear factor erythroid-related factor 2, and increased 8-oxo-7,8-dihydro-2'-deoxyguanosine, a marker of DNA damage. SN12 tumor xenografts showed decreased growth when treated with CB-839. Furthermore, PET imaging confirmed that ccRCC tumors exhibited increased tumoral uptake of 18F-(2S,4R)4-fluoroglutamine compared with the kidney in the orthotopic mouse model. This technique can be utilized to follow changes in ccRCC metabolism in vivo. Further development of these paradigms will lead to new treatment options with glutaminase inhibitors and the utility of PET to identify and manage patients with ccRCC who are likely to respond to glutaminase inhibitors in the clinic.

AB - Many cancers appear to activate intrinsic antioxidant systems as a means to counteract oxidative stress. Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogenous glutamine for growth and exhibit reprogrammed glutamine metabolism, at least in part due to the glutathione pathway, an efficient cellular buffering system that counteracts reactive oxygen species and other oxidants. We show here that ccRCC xenograft tumors under the renal capsule exhibit enhanced oxidative stress compared with adjacent normal tissue and the contralateral kidney. Upon glutaminase inhibition with CB-839 or BPTES, the RCC cell lines SN12PM-6-1 (SN12) and 786-O exhibited decreased survival and pronounced apoptosis associated with a decreased GSH/GSSG ratio, augmented nuclear factor erythroid-related factor 2, and increased 8-oxo-7,8-dihydro-2'-deoxyguanosine, a marker of DNA damage. SN12 tumor xenografts showed decreased growth when treated with CB-839. Furthermore, PET imaging confirmed that ccRCC tumors exhibited increased tumoral uptake of 18F-(2S,4R)4-fluoroglutamine compared with the kidney in the orthotopic mouse model. This technique can be utilized to follow changes in ccRCC metabolism in vivo. Further development of these paradigms will lead to new treatment options with glutaminase inhibitors and the utility of PET to identify and manage patients with ccRCC who are likely to respond to glutaminase inhibitors in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=85037698498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037698498&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-0930

DO - 10.1158/0008-5472.CAN-17-0930

M3 - Article

VL - 77

SP - 6746

EP - 6758

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 23

ER -